Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Achillion Stock Jumps 83% As FDA Lifts Clinical Hold On Hepatitis C Drug

RELATED NEWS
Trade ACHN now with 

Shares of Achillion Pharmaceuticals Inc. (ACHN: Quote) surged 83 percent on Tuesday after the U.S. Food and Drug Administration lifted the clinical hold on the company's investigational hepatitis C drug sovaprevir.

This is the second time in as many days that Achillion shares have seen a rally. Yesterday, the stock surged to its highest level since late January, as investors, seeing promise for its hepatitis C pipeline, speculated that Achillino could be a takeover target.

It was about a year ago, when the FDA placed a clinical hold on Achillion's sovaprevir after elevated liver enzyme levels were observed in patients, due to higher-than-expected exposures to sovaprevir and another drug, atazanavir.

The FDA move to lift clinical hold indicates Achillion can conduct trials with a maximum of 200 mg once daily of sovaprevir in hepatitis C viral infection (HCV) patients and in single dose trials in healthy volunteers.

However, the FDA has maintained a partial clinical hold for multiple dose studies of sovaprevir that may be conducted in healthy volunteers, requiring prior review and approval of the protocol by the Agency.

Achillion said that the previously evaluated dose of sovaprevir—which was well-tolerated with clinical activity in two completed Phase 2 studies—may be used in additional therapeutic clinical trials.

The development at Achillion comes at a time when hepatitis C drug makers are seen as promising acquisition targets. Merck (MRK) on Monday agreed to acquire Idenix Pharmaceuticals (IDIX), a developer of hepatitis C drugs, for $3.85 billion.

A biopharmaceutical company, New Haven, Connecticut-based Achillion focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company currently has no products on the market.

Sovaprevir is a Phase 2 NS3/4A protease inhibitor being developed for the potential treatment of chronic HCV infection. To date, about 550 subjects have been exposed to sovaprevir with clinical activity reported in two Phase 2 12-week treatment duration studies.

The hepatitis C virus is the most common cause of viral hepatitis, which is an inflammation of the liver. It is currently estimated that more than 150 million people are infected with HCV worldwide including more than 5 million people in the U.S.

Achillion stock closed Tuesday at $7.79, up $3.54 or 83.29%, on a volume of 74 million shares on the Nasdaq. In after hours, the stock dropped $0.11 or 1.41%, to trade at $7.68.

Register
To receive FREE breaking news email alerts for Achillion Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving sharply lower at the open, stocks showed a substantial recovery attempt over the course of the trading day on Monday. The Nasdaq and the S&P 500 bounced well off the one-month intraday lows set in early trading but still closed in the red. While most Americans oppose sending ground troops into combat operations against the terrorist group known as ISIS, the results of a CNN/ORC International poll found that an even larger majority think the American military will still end up putting boots on the ground. With incumbent Sen. Kay Hagan, D-N.C., and Republican challenger Thom Tillis running nearly neck-and-neck in the North Carolina Senate race, the results of a new CNN/ORC International survey suggest that the race could be decided by the number of votes for Libertarian candidate Sean Haugh.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.